Lexicon Pharmaceuticals Stock (NASDAQ:LXRX)
Previous Close
$0.51
52W Range
$0.28 - $2.45
50D Avg
$0.52
200D Avg
$1.18
Market Cap
$180.75M
Avg Vol (3M)
$15.38M
Beta
1.03
Div Yield
-
LXRX Company Profile
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
LXRX Performance
Peer Comparison
| Ticker | Company |
|---|---|
| HEPA | Hepion Pharmaceuticals, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| BLRX | BioLineRx Ltd. |
| MREO | Mereo BioPharma Group plc |
| OCEA | Ocean Biomedical, Inc. |
| IBRX | ImmunityBio, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| MCRB | Seres Therapeutics, Inc. |
| ARDX | Ardelyx, Inc. |
| HOOK | HOOKIPA Pharma Inc. |
| ELEV | Elevation Oncology, Inc. |
| ENVB | Enveric Biosciences, Inc. |